Brooks Automation

Azenta announced the immediate resignation of CEO, president and director John Marotta; the stock plunged intraday by about 10.4% from $37.40 to as low as $31.90. Dr. Martin Madaus will serve as interim CEO, and the search for a permanent successor is being handled by Heidrick & Struggles. The company confirmed its revenue guidance but announced a one-time consulting charge of about $3 million in adjusted EBITDA, which, together with leadership uncertainty, intensified downward pressure on the share price. » More on de.investing.com

Azenta reported Q3 fiscal 2026 revenue of $161 million, up 12% year over year and 9% organically, driven by recurring-revenue businesses and improved Multiomics performance. Adjusted EBITDA margin rose sequentially to 11.4% and non-GAAP EPS was $0.16, while the company held $529 million in cash and no debt. Management raised full-year revenue guidance to $613 million–$618 million and expects adjusted EBITDA of $59 million–$62 million, and repurchased $50 million of shares during the quarter. Operational actions include standardizing Automated Stores, cost reductions and modular product strategies to improve scalability and profitability. » More on finance.yahoo.com

Brooks Automation, a company specializing in robotics and software automation, is in talks with potential advisers about a possible initial public offering. The firm, backed by Thomas H. Lee Partners, was spun off in a $3 billion transaction in 2021/22. Brooks supplies robotic and automation platforms for semiconductor manufacturing, the life sciences and other high-tech industries and employs more than 2,000 people across about 14 countries. Discussions are ongoing and the details of any offering could still change. » More on de.investing.com

Azenta reported Q2 2026 revenue of $145m (organic -3%), missing consensus, and posted a non‑GAAP EPS loss of $0.04. The company recorded a non‑cash goodwill impairment of $149.1m and cut its full‑year revenue outlook to $603–621m while sharply lowering its expected EBITDA margin. The stock fell about 22% premarket to $19; Azenta stresses a strong balance sheet with $565m cash and no debt. Management expects continued demand pressure, pushes back the timeline for a sustained recovery and is focusing on operational measures. » More on de.investing.com

Azenta has named Trey Martin president of its multiomics business; he will assume the role on April 6, 2026 and report to CEO John Marotta. Ginger Zhou is stepping down as president and will remain with the company as an advisor until November 2026. The appointment follows plans to expand global synthesis capacity; Martin brings more than 30 years of experience from Maravai, Danaher and IDT. The stock has recently shown high volatility: since the start of the year it is at $21.62, down about 32%, although it rose 6.9% in the prior week. » More on de.investing.com